BioElectronics Corporation (OTC: BIEL), a developer of medical technology products, released an update from its Chairman, Richard Staelin, PhD, detailing sales growth, cost control achievements, and progress in strategic initiatives. The company reported a small profit for calendar year 2025, attributed to disciplined cost control measures including office relocation and staff reduction.
To drive revenue, BioElectronics launched targeted advertising campaigns aimed at medical professionals and healthcare providers to expand clinical awareness of its RecoveryRx device among surgeons, pain specialists, and rehabilitation providers seeking non-opioid pain management options. Additionally, consumer-focused social media advertising targeting Generation X consumers aims to increase brand visibility for drug-free solutions for chronic musculoskeletal pain.
The company continues outreach to physician-owned ambulatory surgical centers and orthopedic practices to identify a clinical trial partner for RecoveryRx. The objective is to participate in a postoperative clinical study that may support future qualification for reimbursement under the federal NO PAIN Act initiative, which represents a meaningful long-term opportunity for broader adoption of non-opioid pain management technologies in surgical settings.
Internationally, BioElectronics is working with legal counsel in Singapore and funders in China regarding arbitration proceedings involving a former distributor believed to have breached contractual obligations. The company remains committed to protecting its intellectual property and contractual rights.
A significant milestone is the advancement of the strategic distribution and licensing relationship with Electrome Corporation. Initial conditions of the supply agreement have been satisfied, with Electrome placing its initial purchase order. Manufacturing is underway, and Electrome is planning a commercial launch of BioElectronics' pulsed shortwave therapy products through its platform. This partnership provides another pathway to increase consumer awareness and access to FDA-cleared, drug-free pain therapy products.
Chairman Staelin emphasized that while the Electrome relationship is important, it is part of a broader strategy including clinical market development, direct professional outreach, consumer education, and international opportunities. Despite challenges faced by emerging medical technology companies, BioElectronics is encouraged by growing interest in non-drug pain management solutions and believes it is well positioned in the evolving electroceutical and non-opioid pain management markets.
More information about BioElectronics can be found at https://www.bielcorp.com/.
